<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362035</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-LY-005</org_study_id>
    <nct_id>NCT02362035</nct_id>
  </id_info>
  <brief_title>ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies</brief_title>
  <acronym>KEYNOTE145</acronym>
  <official_title>A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and
      pembrolizumab in hematologic malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (AEs)</measure>
    <time_frame>104 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Non-hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Richter's Syndrome</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Safety Review</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The safety and preliminary efficacy of the combination of acalabrutinib and pembrolizumab will be reviewed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acalabrutinib</intervention_name>
    <description>oral</description>
    <arm_group_label>Safety Review</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Safety Review</arm_group_label>
    <other_name>KEYTRUDA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Diagnosis of a hematologic malignancy as documented by medical records and with
             histology based on criteria established by the World Health Organization (WHO).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.

          -  Agreement to use contraception during the study and for 90 days after the last dose of
             ACP-196 or 120 days after the last dose of pembrolizumab, if sexually active and able
             to bear or beget children.

          -  Completion of all therapy (including surgery, radiotherapy, chemotherapy,
             immunotherapy, or investigational therapy) for the treatment of cancer ≥ 4 weeks
             before the start of study therapy.

          -  ANC ≥ 0.5 x 10^9/L or platelet count ≥ 50 x 10^9/L unless due to disease involvement
             in the bone marrow.

        Main Exclusion Criteria:

          -  A life-threatening illness, medical condition or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, interfere with the
             absorption or metabolism of study drugs, or put the study outcomes at undue risk.

          -  Central nervous system (CNS) involvement by lymphoma/leukemia

          -  Any therapeutic antibody within 4 weeks of first dose of study drugs.

          -  Total bilirubin &gt; 1.5 x ULN; and aspartate aminotransferase (AST) or alanine
             aminotransferase (ALT) &gt; 3.0 x ULN.

          -  Estimated creatinine clearance of &lt; 30 mL/min, calculated using the formula of
             Cockcroft and Gault (140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if
             female.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dih-Yih Chen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acerta Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2015</study_first_submitted>
  <study_first_submitted_qc>February 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2015</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bruton tyrosine kinase inhibitor</keyword>
  <keyword>Btk</keyword>
  <keyword>B-Cell Malignancies</keyword>
  <keyword>Mantle Cell</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Follicular</keyword>
  <keyword>Waldenstrom</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>marginal zone lymphomas</keyword>
  <keyword>hairy cell leukemia</keyword>
  <keyword>B cell acute lymphoid leukemia</keyword>
  <keyword>Acalabrutinib</keyword>
  <keyword>ACP-196</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

